<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3350">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02140801</url>
  </required_header>
  <id_info>
    <org_study_id>ISSBRIL0361</org_study_id>
    <nct_id>NCT02140801</nct_id>
  </id_info>
  <brief_title>Optical Coherence Tomography to Evaluate Ticagrelor and Clopidogrel</brief_title>
  <official_title>A Randomised, Open-label, Parallel Group, Multi-center Study Using OCT to Comparing the Efficacy and Safety of Ticagrelor With Clopidogrel in the Prevention of Subclinical Thrombus in Patients After Drug-eluting Stent Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Hospital of Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Hospital of Nanjing Medical University</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A number of 352 patients scheduled for elective percutaneous coronary intervention (PCI)
      with a native coronary stenosis suitable for DES implantation and OCT imaging are openly
      randomized 1:1 to either BRILINTA™ (ticagrelor) or Plavix® (clopidogrel bisulfate).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is prospectively conducted at 4 high-volume PCI center in China with OCT
      expertise. Angiographic follow-up and OCT imaging with motorized pull-back at 1 mm/s are
      planned in all patients 12 months after implantation of the study stents. OCT endpoints are:
      (1) Subclinical intra-stent thrombus, defined as a mass protruding to the lumen with
      significant attenuation, and respectively (2) endothelial coverage, expressed as % of struts
      without coverage and % of stent length containing non-covered struts. The study is powered
      for OCT endpoints, which are likely to reach significance at the level P &lt; 0.05 even at a
      follow-up drop-out rate up to 10%.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Stent thrombus</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The occurrence of subclinical thrombus as detected by OCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelial coverage of the stent struts assessed by optical coherence tomography</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neointimal proliferation within the stent assessed by optical coherence tomography</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent malapposition assessed by optical coherence tomography</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Edge dissections assessed by optical coherence tomography</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Bleeding events</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">352</enrollment>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor  90mg tablet, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clopidogrel 75mg tablet, daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Plain, round, yellow, filmcoated tablet, 90 mg</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <other_name>BRILINTA™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Orange brown capsule, containing one 75 mg clopidogrel tablet (cut into 2 halves)</description>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>Plavix®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures;

          -  Men and women  18 years and older;.

          -  Established indication to PCI according to the guidelines of American Heart
             Association and American College of Cardiology;

          -  Native coronary lesion suitable for drug-eluting stent placement and OCT imaging.

        Exclusion Criteria:

          -  Pregnancy and breast feeding mother;

          -  Co-morbidity with an estimated life expectancy of &lt; 50 % at 12 months;

          -  Scheduled major surgery in the next 6 months;

          -  Inability to follow the protocol and comply with follow-up requirements or any other
             reason that the investigator feels would place the patient at increased risk;

          -  Previous enrolment in this study or treatment with an investigational drug or device
             under another study protocol in the past 30 days

          -  Cardiogenic shock

          -  Previous subacute or late coronary stent thrombosis

          -  Known allergy against ticagrelor, or against clopidogrel, or aspirin

          -  History of major hemorrahage (intracranial, gastrointestinal, etc.)

          -  Active pathological bleeding

          -  Acute or chronic hematologic disorder including a Hemoglobin less than 10 g/L or a
             platelet count less than 10×109/L before procedure

          -  Any history of Severe renal or hepatic dysfunction (hepatic failure, cirrhosis,
             portal hypertension and active hepatitis);

          -  Neutropenia,

          -  thrombocytopenia;

          -  Known acute pancreatitis

          -  Arterial aneurysm, arterial/venous malformation and aorta dissection.

          -  Culprit lesion within the proximal 10 mm of the right or left coronary artery

          -  Saphenous vein grafts

          -  Lesion length &gt; 30 mm

          -  Involves a side branch ≥2.0 mm in diameter by visual estimate which requires treatmen

          -  In-stent restenotic lesions

          -  Thombus-containing lesions
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaoliang Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanjing First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shaoliang Chen, MD</last_name>
    <phone>+86 13605157029</phone>
    <email>chmengx@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Kan, MBBS</last_name>
    <phone>+86 15305140515</phone>
    <email>kanjingok@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaoliang Chen, MD</last_name>
      <phone>+86 13605157029</phone>
      <email>chmengx@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Jing Kan, MBBS</last_name>
      <phone>+86 15305140515</phone>
      <email>kanjingok@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>May 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Hospital of Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Shaoliang Chen</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Drug-eluting stent</keyword>
  <keyword>Stent thombosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
